Analyst Ratings for [BMRN] BioMarin Pharmaceutical Inc.

2/24/25	Upgrades	Perform Outperform	X
BMRN BioMarin Pharmaceutical Oppenheimer
$98
11/15/24	Initiated	Outperform	X
BMRN BioMarin Pharmaceutical Wolfe Research
$95
10/30/24	Downgrades	Outperform Mkt Perform	X
BMRN BioMarin Pharmaceutical William Blair
10/10/24	Resumed	Outperform	X
BMRN BioMarin Pharmaceutical Raymond James
$79
8/20/24	Upgrades	Mkt Perform Outperform	X
BMRN BioMarin Pharmaceutical Bernstein
$94 $110
5/17/24	Downgrades	Outperform Neutral	X
BMRN BioMarin Pharmaceutical Robert W. Baird
$104 $72
5/14/24	Initiated	Outperform	X
BMRN BioMarin Pharmaceutical Evercore ISI
$113
11/15/23	Initiated	Overweight	X
BMRN BioMarin Pharmaceutical Wells Fargo
$100
10/23/23	Upgrades	Underperform Mkt Perform	X
BMRN BioMarin Pharmaceutical Bernstein
$82
9/28/23	Initiated	Mkt Perform	X
BMRN BioMarin Pharmaceutical Raymond James
9/18/23	Initiated	Buy	X
BMRN BioMarin Pharmaceutical UBS
$120
7/27/23	Initiated	Sector Perform	X
BMRN BioMarin Pharmaceutical Scotiabank
$95
7/5/23	Upgrades	Mkt Perform Outperform	X
BMRN BioMarin Pharmaceutical BMO Capital Markets
$102
6/14/23	Resumed	Outperform	X
BMRN BioMarin Pharmaceutical Credit Suisse
$120
3/21/23	Initiated	Underperform	X
BMRN BioMarin Pharmaceutical Bernstein
$81
2/22/23	Downgrades	Outperform Perform	X
BMRN BioMarin Pharmaceutical Oppenheimer
2/21/23	Initiated	Neutral	X
BMRN BioMarin Pharmaceutical Citigroup
$116
1/30/23	Initiated	Market Perform	X
BMRN BioMarin Pharmaceutical BMO Capital Markets
$107
1/18/23	Initiated	Hold	X
BMRN BioMarin Pharmaceutical Canaccord Genuity
$119
10/31/22	Upgrades	Perform Outperform	X
BMRN BioMarin Pharmaceutical Oppenheimer
$92 $110
7/13/22	Initiated	Overweight	X
BMRN BioMarin Pharmaceutical Cantor Fitzgerald
$110
6/13/22	Resumed	Neutral	X
BMRN BioMarin Pharm Wedbush
$146 $70
4/25/22	Upgrades	Eq-Weight Overweight	X
BMRN BioMarin Pharm Morgan Stanley
$96 $113
11/22/21	Upgrades	Mkt Perform Outperform	X
BMRN BioMarin Pharm William Blair
10/7/21	Resumed	Buy	X
BMRN BioMarin Pharm Jefferies
$100
6/4/21	Resumed	Outperform	X
BMRN BioMarin Pharm Robert W. Baird
$101
4/26/21	Resumed	Outperform	X
BMRN BioMarin Pharm Credit Suisse
$102
3/4/21	Resumed	Buy	X
BMRN BioMarin Pharm Guggenheim
3/1/21	Upgrades	In-line Outperform	X
BMRN BioMarin Pharm Evercore ISI
$90 $100
5/23/19	Resumed	Buy	X
BMRN BioMarin Pharm Citigroup
4/9/19	Resumed	Outperform	X
BMRN BioMarin Pharm Raymond James
1/2/19	Downgrades	Outperform Mkt Perform	X
BMRN BioMarin Pharm Raymond James
12/14/18	Initiated	Outperform	X
BMRN BioMarin Pharm Wolfe Research
10/1/18	Initiated	Overweight	X
BMRN BioMarin Pharm Cantor Fitzgerald
$126
8/7/18	Reiterated	Buy	X
BMRN BioMarin Pharm Stifel
$109 $114
8/3/18	Reiterated	Buy	X
BMRN BioMarin Pharm Stifel
$102 $109
5/16/18	Initiated	Buy	X
BMRN BioMarin Pharm Canaccord Genuity
$101

BMRN BioMarin Pharmaceutical Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.